Research compound
CJC without DAC / modified GRF
A label often used for a shorter-acting GHRH analogue.
Also discussed as: Modified GRF 1-29 · CJC-1295 no DAC
THE RESEARCH QUESTION
What is being investigated?
This name is often grouped with CJC-1295, although removing the long-acting component changes the product being discussed.
EVIDENCE SNAPSHOT
Evidence cannot be transferred
The human CJC-1295 study cited here examined a long-acting analogue. It should not be used to validate a different compound sold under the ‘without DAC’ name.
LIMITS & SAFETY
What should you know?
Identity, duration and safety require separate evaluation.
FOLLOW THE EVIDENCE
Sources & further reading
- CJC-1295: GH and IGF-I study in healthy adults (2006) ↗Human study
- Huberman Lab: Benefits & Risks of Peptide Therapeutics (2024) ↗Commentary
Checked 8 October 2026. Sources may describe different populations, formulations and jurisdictions. This overview is not a systematic review or individual medical advice.
PUT THE EVIDENCE IN CONTEXT
Questions about what you’ve read?
Request an educational conversation with Matthew about the evidence and questions to raise with your medical professional.